Active, Not Recruiting
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer - CA209-907
Updated: 11 September, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Non small cell lung cancer (Squamous or non-squamous) - At least one prior anti-cancer therapy that did not work - ECOG Performance Scale 0-1 Exclusion Criteria: - Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug - Active, known or suspected autoimmune disease or infection - Prior immuno-oncology therapy - Corticosteroids within 2 weeks of study drug administration Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
